British Adendra Therapeutics closes $53m financing
The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
US-Greek Venture gets 32m cash injection
/in News/by Thomas GabrielczykUS cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received 32m in funding by Enterprise Greece.
EC signs prepurchase agreement with Valneva
/in News/by Thomas GabrielczykThe European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Novo Nordisk snatches Dicerna
/in News/by Thomas GabrielczykNovo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
LSP and EQT merge to create top-10 investment firm
/in News/by Thomas GabrielczykLife Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Novartis inks US-$1.3bn deal with Dunad Therapeutics
/in News/by Thomas GabrielczykDunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
Agomab Therapeutics to acquire Origo Biopharma
/in News/by Thomas GabrielczykBelgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Sofinnova Capital X Fund closed at 472m
/in News/by Thomas GabrielczykParis-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
Curevac withdraws MAA of CVnCoV
/in News/by Thomas GabrielczykGerman CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Delivering on Europe´s Green Deal EFIB 2021 in Vienna
/in News/by Thomas GabrielczykLeading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, […]